Obsidian Therapeutics, Inc.
Sağlık
NOT REVIEWED — A definitive compliance result cannot be given for this company because one or more ratios could not be calculated.
$13
Price (1 Year)
Participation Finance Screening Ratios
Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.
About the Company
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer.
Website ↗